
PLOS ONE study finds that PPI users have up to a 21% increased risk of heart attack compared to patients who take H2 blockers (Pepcid, Zantac, Tagamet).
PLOS ONE study finds that PPI users have up to a 21% increased risk of heart attack compared to patients who take H2 blockers (Pepcid, Zantac, Tagamet).